Tatva Chintan Pharma Chem Ltd

- There is no mention of any current or planned new fundraising through debt or equity in the earnings call transcript. - The company has fully utilized its net IPO proceeds of ₹2,072.81 million as of 31 March 2024. - The transcript focuses on operational updates, capacity expansion plans, and expected revenue growth but does not indicate plans for additional capital raising. - CAPEX for FY25 and FY26 is planned at around ₹70 crores, to be funded from internal accruals, with no equity or debt fundraising mentioned. - Soil testing issues have delayed new plant construction but no mention of raising funds to resolve this. - Overall, no new debt or equity fundraising is disclosed for immediate or near-future needs.

- Planned CAPEX for FY25 and FY26 is around Rs. 70 crores. - CAPEX was delayed due to unfavorable soil test results at the identified site for a multi-story plant. - The company is testing three alternative sites; if unsuitable, may scale down plant from 7 floors to 4 floors. - The new plant is critical to address capacity constraints expected by FY26. - Additional investments include setting up a solvent recovery & distillation plant (commissioning by May-June) and a bromine recovery plant (by August-September). - Waste treatment setups are being considered within existing premises to optimize plant utilization. - The company aims for a multi-story building with maximum reactors for future growth but is flexible based on soil test outcomes.

- SDA segment volume expected to grow nearly 50% in FY25 with 25% revenue growth due to raw material price reductions; further 30-40% volume growth expected in FY26 driven by Euro 7 implementation. - Electrolyte Salts revenue projected to increase by around 150-160% in FY25. - PASC segment anticipated to grow 80-90% in FY25, with commercial production started for some products. - Phase Transfer Catalysts (PTC) expected to grow 8-10% in FY25 despite price declines. - New automotive customers expected to contribute significant volumes, with roughly 15% of their existing business volume expected in FY25; relationship build-up may take a couple of years. - Capacity constraints anticipated by end-FY25 with utilization reaching 85-90%; CAPEX of Rs.70 crore planned to expand capacity. - Long-term growth seen from innovative products and new site plant expansion despite some delays due to soil testing.

- FY25 topline growth expected: Electrolyte Salts revenue to grow 150-160%, PASC 80-90%, PTC 8-10%, SDA 15-20%. - Overall volume growth and capacity utilization to increase, with SDA volume growth around 50% and volume growth expected from new and existing customers. - EBITDA margins targeted to improve to 22-24% in FY25 from ~17% in FY24 due to better absorption of fixed overhead costs as volumes rise. - Employee costs currently at 14-15% of revenue expected to reduce proportionally as revenue grows. - Price reductions in SDAs expected to stabilize by Q2 FY25, enabling margin maintenance. - CAPEX planned at Rs. 70 crores for FY25 and FY26 to address capacity constraints and enable further growth. - New plant delays due to soil testing issues may slightly impact near-term capacity but alternative sites are being evaluated. - Longer-term optimism for revenue growth beyond FY25 linked to new product commercialization and market expansion, including BS VII opportunity targeting FY26.

- Commercial supplies have started with one of the two new automotive catalyst customers; the second is pending REACH registration expected within two months. - Deliveries of a couple of hundred tonnes have been made to a new large customer for multiple applications with good off-take, though volumes are currently small compared to existing largest customers. - Existing largest customers have approved two new products, expected to increase volumes by approximately 40%-45%, with commercial orders booked and a third application expected to commence deliveries between October and December 2024. - Validation and commercial supplies have started for five pharma/agro intermediary products, with full commercialization expected from September 2024 to early 2025. - Specialties like SDAs expect nearly 50% volume growth in FY25 supported by new and existing customers, although price reductions may constrain revenue growth. - Order buildup and inventory creation have been done for certain products to avoid missing volume opportunities due to capacity constraints.